Skip to main contentAI and Advanced
/
SYNCOMF · NSEBSE SENSEX74,294.96-0.03%BSE |
NIFTY 5023,346.4+0.33%NSE |
NIFTY BANK56,358.7+0.54%NSE |
NIFTY IT28,854.55-1.03%NSE |
NIFTY AUTO27,129-0.11%NSE |
NIFTY FMCG45,466.8-0.23%NSE |
NIFTY PHARMA26,710.1+0.49%NSE |
NIFTY 50022,840.55+0.82%NSE |
SY
NSE · Equity shares · Biotechnology & Drugs1.26 · 6.71%
Syncom Formulations India Ltd SYNCOMF
NSE:INR 20.04
BSE:INR 20.15
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections8 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for SYNCOMF
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 18.78
Day rangeINR 18.8 — INR 20.25
52-week rangeINR 10.21 — INR 22.59
Volume1.02 Cr
Market cap1,255.84
P/E11.57
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)489.17
Net Income (INR Cr)76.44
Rev Growth (5 Year %)14.85
EPS Growth (5 Year %)17.01
P/E Ratio11.57
Book Value4.41
EPS0.81
Price/BV4.54Computed
Research path: Interpret Syncom Formulations India Ltd's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
SYNCOMFSyncom Formulations India Ltd1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 533.85 | 413.28 | 404.66 |
| Cash Equivalents | 5.15 | 0 | 63.02 |
| Other Liabilities Total | 7.01 | 5.52 | 5.35 |
| Common Stock Total | 94 | 84.41 | 94 |
| Other Current Assets Total | 33.27 | 1.66 | 0.13 |
| Total Assets | 533.85 | 413.28 | 404.66 |
| Cash | 1.19 | 0.66 | 4.76 |
| Total Equity | 414.99 | 342.16 | 288.14 |
| Long Term Investments | 111.3 | 64.26 | 56.74 |
| Retained Earnings(Accumulated Deficit) | 320.99 | 223.78 | 169.76 |
| Total Common Shares Outstanding | 94 | 94 | 94 |
| Tangible Book Valueper Share Common Eq | 4.41 | 3.64 | 3.06 |
| Total Liabilities | 118.86 | 71.12 | 116.52 |
| Total Debt | 1.47 | 4.58 | 72.49 |
| Short Term Investments | 110.33 | 92.75 | 67.82 |
| Cashand Short Term Investments | 116.67 | 93.41 | 135.6 |
| Total Receivables Net | 117.54 | 128.78 | 114.01 |
| Notes Payable/Short Term Debt | 1.47 | 4.58 | 72.49 |
| Deferred Income Tax | 8.12 | 6.31 | 4.98 |
| Accounts Receivable-Trade Net | 110.5 | 107.73 | 103.41 |
| Property/Plant/Equipment Total-Net | 89.77 | 77.53 | 72.31 |
| Total Current Liabilities | 103.73 | 59.3 | 106.2 |
| Total Inventory | 62.88 | 45.79 | 24.71 |
| Accounts Payable | 74.39 | 42.8 | 24.14 |
| Other Currentliabilities Total | 27.86 | 11.84 | 8.94 |
| Intangibles Net | 0.4 | 0.05 | 0.11 |
| Other Long Term Assets Total | 1.31 | 0.82 | 0.21 |
| Note Receivable-Long Term | 0.71 | 0.67 | 0.52 |
| Total Current Assets | 330.37 | 269.97 | 274.78 |
| Accumulated Depreciation Total | Not available | -67.39 | -62.65 |
| Accrued Expenses | Not available | 0.08 | 0.63 |
| Prepaid Expenses | Not available | 0.34 | 0.33 |
| Additional Paid-In Capital | Not available | 24.38 | 24.38 |
| Property/Plant/Equipment Total-Gross | Not available | 144.91 | 134.96 |
| Total Long Term Debt | Not available | 0 | 0 |
| Unrealized Gain(Loss) | Not available | 9.59 | Not available |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio0.28
Price to Sale Ratio2.57
Growth
Debt 5Yr CAGR %-52.67
Margins
Operating Margin 12m14.5
Operating Margin 5y Avg11.28
Net Profit Margin 12m15.63
Net Profit Margin 5y11.5
Yield
Dividend Yield %0
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk43.15
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,936.1 | 4.65 L | 38.4 | — |
| Divi's Laboratories | INR 7,367.95 | 1.96 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,978.95 | 1.69 L | 72.73 | — |
| Cipla | INR 1,407.8 | 1.14 L | 27.57 | — |
| Zydus Lifesciences | INR 1,121.8 | 1.12 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 50.57%
- FII
- 0.35%
- Other
- 49.08%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Relevant company news is unavailable.
Corporate actions
Events
- board MeetingsAudited Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- board MeetingsQuarterly Results & A.G.M.
- board MeetingsAudited Results
- board MeetingsTo consider other business matters.
- board MeetingsQuarterly Results
Rusaka Markets Community
Discussion and sentiment for Syncom Formulations India Ltd
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Syncom Formulations (India) Limited is an India-based company that is engaged in the pharmaceutical business. The Company is engaged in the development, manufacturing & sale of pharmaceutical products and services& trading of commodities and renting of properties. The Company manufactures and markets more than 200 pharmaceutical formulation products in various dosage forms, like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections and Dry Vial injections, Dry Syrups, Ointments and Inhalers. The Company's domestic division product categories include Cratus Life Care, Cratus Evolve and Cratus Right Nutrition. Its products include Ciprofloxacin Tablets USP 250 mg, Ciprofloxacin Tablets USP 500 mg, Ciprofloxacin Tablets USP 750 mg, Cefazolin For Injection USP 1 gm, Cefotaxime For Injection USP 1 gm, Ceftriaxone for Injection USP 500 mg, Albendazole Oral Suspension USP 100mg, Cetirizine Oral Solution BP, Clotrimazole Cream USP, Compound Benzoic Acid Ointment BP, and others.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- SYNCOMF
- BSE Code
- 524470
Questions
Stock FAQ
What is the symbol and ISIN of Syncom Formulations India Ltd?
Syncom Formulations India Ltd has the symbol SYNCOMF and ISIN - INE312C01025.
What is the current price of Syncom Formulations India Ltd?
Syncom Formulations India Ltd is currently trading at INR 20.04.
What are the year high and year low of Syncom Formulations India Ltd?
Syncom Formulations India Ltd has a year high of INR 22.59 and a year low of INR 10.21.
What is the market capitalization of Syncom Formulations India Ltd?
Syncom Formulations India Ltd has a market capitalization of INR 1,255.84 crore.
What is the P/E ratio of Syncom Formulations India Ltd?
Syncom Formulations India Ltd has a P/E ratio of 11.57.
What is the dividend yield of Syncom Formulations India Ltd?
Syncom Formulations India Ltd has a dividend yield of 0.00%.
How is the financial performance of Syncom Formulations India Ltd based on revenue, net income, and EPS?
Syncom Formulations India Ltd has revenue of INR 489.17 crore, net income of INR 76.44 crore, and EPS of INR 0.89.
What is the book value of Syncom Formulations India Ltd?
Syncom Formulations India Ltd has a book value of INR 4.41.
What is the debt-to-equity ratio of Syncom Formulations India Ltd?
Syncom Formulations India Ltd has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Syncom Formulations India Ltd?
Syncom Formulations India Ltd has a price-to-book ratio of 4.54 and a price-to-sales ratio of 2.57.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.